Market Cap
$49.2M
SCYX
SCYNEXIS INC
$5.12 ▼ -4.66%
Prev close $5.37Market cap$49.2M
ConsensusStrong Buy
12-mo target$36.33 (+609.6%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on SCYX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
21 funds
Inst. Value
$7.1M
Insider Activity
$0.00 buy / $0.00 sell
Social Sentiment
33° Cool
SEC Reports
5
Press Releases
2
Price chart 30d -4.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 contract
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or t
Sep 18, 2026 Insider
Burke Steven Keith was granted 5,750 shares
Director
Sep 18, 2026 Insider
Sep 10, 2026 SEC Burke Steven Keith was granted 5,750 shares
Director
SCYNEXIS announced the retirement of CFO Ivor Macleod effective September 9, 2026, and the immediate appointment of Sanj
8-K — Impact 2/10
Sep 9, 2026 Insider
Jun 26, 2026 SEC Subramanian Sanjay was granted 100,000 shares
Chief Financial Officer
SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M to 60M shares (post
8-K — Impact 3/10
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M
8-K — Impact 4/10
Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant
Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 9 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 13, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Aug 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jul 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Price targets
Where 3 covering analysts think SCYX trades over the next 12 months.
$36.33 +609.6% upside Strong Buy
Current$5.12 Low$32.00 Median$33.00 High$44.00 3 analysts
$32.00$44.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 4 neutral · avg impact 3.8/10.Plus 2 press releases.
NEUTRAL8-K2/10
SCYNEXIS announced the retirement of CFO Ivor Macleod effective September 9, 2026, and the immediate
Sep 10, 2026
NEUTRAL8-K3/10
SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M
Jun 26, 2026
NEUTRAL8-K4/10
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8
May 22, 2026
BEARISHPRESS-RELEASE7/10
SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than
May 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
contract
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology comp
Sep 10, 2026
other
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth ac
Sep 8, 2026
Clinical Trial
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Phase Phase 3 — TERMINATED
Aug 25, 2026
other
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innov
Aug 17, 2026
earnings_calendar
SCYX Q2 2026 Earnings Scheduled — 2026-08-17
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.72 | $-0.79–$-0.65 | 47.1% | -42.1% | 0↑ 1↓ | $0.0B | 2 |
| Next Q | $-0.68 | $-0.71–$-0.64 | -133.8% | +6.2% | 1↑ 0↓ | $0.0B | 2 |
| Current FY | $-2.91 | $-3.03–$-2.79 | -114.0% | +28.7% | 1↑ 0↓ | $0.0B | 2 |
| Next FY | $-2.31 | $-2.95–$-1.68 | 20.4% | +8.1% | 1↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.720 | — |
| 7d ago | $-0.507 | -0.213 |
| 30d ago | $-0.507 | -0.213 |
| 60d ago | $-0.507 | -0.213 |
| 90d ago | $-0.560 | -0.160 |
Institutional ownership
Which big funds own SCYX (from quarterly 13F filings) and who is adding or trimming.
21 institutional holders with $7.1M total value (1,748,000 shares) as of 2026-Q2. Top holders: ADAGE, Woodline, VANGUARD.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 543,478 | $2.2M | 31.1% | — |
| Woodline Partners LP | 387,520 | $1.6M | 22.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 296,747 | $1.2M | 17.0% | — |
| MILLENNIUM MANAGEMENT LLC | 180,788 | $735.8K | 10.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 82,093 | $334.2K | 4.7% | — |
| RENAISSANCE TECHNOLOGIES LLC | 76,525 | $311.5K | 4.4% | — |
| VANGUARD FIDUCIARY TRUST CO | 57,970 | $235.9K | 3.3% | — |
| BlackRock, Inc. | 41,522 | $169.0K | 2.4% | — |
| NORTHERN TRUST CORP | 22,385 | $91.1K | 1.3% | — |
| Empowered Funds, LLC | 15,462 | $62.9K | 0.9% | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 18 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Burke Steven Keith | Director | AWARD | 5,750 | — | — |
| Sep 18, 2026 | Burke Steven Keith | Director | AWARD | 5,750 | — | — |
| Sep 9, 2026 | Subramanian Sanjay | Chief Financial Officer | AWARD | 100,000 | — | — |
| Jun 26, 2026 | HANHAM ANN | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | HANHAM ANN | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | HASTINGS DAVID C | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | HASTINGS DAVID C | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | ANIDO ARMANDO | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | ANIDO ARMANDO | Director | AWARD | 2,875 | — | — |
| Jun 26, 2026 | Macdonald Guy | Director | AWARD | 2,875 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SCYX.
Shares short
459,745
Settlement Sep 15, 2026
Change vs prior
+1.3%
Semi-monthly cycle
Days to cover
9.7
At avg daily volume
Of shares outstanding
≈4.6%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 31, 2026 | LUDP | Volatility Pause | Resumed |
| Jul 31, 2026 | LUDP | Volatility Pause | Resumed |
All SCYX filing & press-release reports (7)
- 8-K reportSep 10, 2026
- 8-K reportJun 26, 2026
- 8-K reportMay 22, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportMar 31, 2026
- PRESS-RELEASE reportMar 4, 2026